References
- Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263–271
- Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361: 496–509
- Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64(Suppl 2)ii14–17
- Mease PJ. Psoriatic arthritis assessment and treatment update. Curr Opin Rheumatol 2009; 21: 348–355
- Ritchlin C. Psoriatic disease – from skin to bone. Nat Clin Pract Rheumatol 2007; 3: 698–706
- Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68: 1387–1394
- Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005; 53: 573
- Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004; 9: 136–139
- Horn EJ, Fox KM, Patel V, et al. Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol 2007; 57: 963–971
- Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 2001; 28: 1842–1846
- United States Department of Health and Human Services – Food and Drug Administration. Product Approval Information – Licensing Action, 2002.
- United States Department of Health and Human Services – Food and Drug Administration. Product Approval Information – Licensing Action. 2004.
- Wu EQ, Feldman SR, Chen L, et al. Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population. Curr Med Res Opin 2008; 24: 3493–34501
- Amgen Inc., Wyeth. Enbrel (etanercept) full prescribing information. 2008.
- Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43: 1130–1139
- Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol 2008; 58: 443–446
- Driessen RJ, Boezeman JB, van de Kerkhof PC, et al. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol 2009; 160: 670–675
- Pearce DJ, Thomas CG, Fleischer AB, Jr, et al. The cost of psoriasis therapies: considerations for therapy selection. Dermatol Nurs 2004; 16: 241–428, 432
- Sizto S, Bansback N, Feldman SR, et al. Economic evaluation of systemic therapies for moderate to severe psoriasis. Br J Dermatol 2009; 160: 1264–1272
- Woolacott N, Bravo Vergel Y, Hawkins N, et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2006; 10: iii–iv, , xiii–xvi, 1–239
- Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006; 10: 1–233, i–iv